Education
About Us
Working with TipRanks
Follow Us
UCB SA (UCBJY)
OTHER OTC:UCBJY
Top Page
UCB SA
(OTC:UCBJY)
Select Model
Select Model
Rating:78Outperform
Price Target:
$130.00
▲(7.59% Upside)
UCB SA's overall stock score is driven by strong financial performance and positive earnings call insights, indicating robust growth and operational efficiency. However, technical indicators suggest potential overbought conditions, and valuation metrics point to a relatively high stock price, which could limit upside potential.
UCB SA (UCBJY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$45.75B
Dividend Yield0.73%
Average Volume (3M)9.36K
Price to Earnings (P/E)31.7
Beta (1Y)0.59
Revenue Growth26.28%
EPS Growth457.14%
CountryUS
Employees9,052
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)2.02
Shares Outstanding389,011,320
10 Day Avg. Volume0
30 Day Avg. Volume9,364
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue6.42
Enterprise Value/Gross Profit8.97
Enterprise Value/Ebitda20.11
Forecast
1Y Price Target
$135.00Price Target Upside11.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
UCB SA Business Overview & Revenue Model
Company DescriptionUCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
How the Company Makes MoneyUCB SA generates revenue primarily through the sale of its pharmaceutical products. Key revenue streams include medications for neurology and immunology, with top-selling products like Vimpat for epilepsy, Neupro for Parkinson's disease, and Cimzia for rheumatoid arthritis. The company invests heavily in research and development to innovate and expand its product portfolio, ensuring sustained growth. Additionally, UCB engages in strategic partnerships and collaborations with other pharmaceutical companies and research institutions to enhance its market presence and product offerings, further contributing to its revenue.
UCB SA Earnings Call Summary
Earnings Call Date:Jul 31, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Feb 19, 2026
Earnings Call Sentiment Positive
The earnings call presents a largely positive outlook with UCB showcasing strong revenue growth, successful product launches, and a robust pipeline. However, challenges such as pricing pressures, currency headwinds, and potential tariffs introduce some uncertainties.Q2-2025 Updates
Positive Updates
Record Growth in Revenue
UCB reported a 26% growth in net sales, reaching EUR 3.32 billion in the first half of 2025, significantly boosted by BIMZELX performance and other recently launched assets.
Successful Product Launches
BIMZELX sales quadrupled to close to EUR 800 million, with strong growth in all regions and indications. The company also saw significant growth in FINTEPLA, RYSTIGGO, and ZILBRYSQ.
Pipeline Development
UCB is advancing its pipeline with multiple new indications and promising clinical results, including a 90% survival rate in TK2 deficiency disorder and positive Phase III results for FINTEPLA in CDKL5 deficiency disorder.
Upgraded Financial Guidance
UCB increased its revenue guidance to at least EUR 7 billion for the full year 2025 and an EBITDA margin to at least 30%, reflecting confidence in continued strong performance.
Strong Market Position
BIMZELX achieved significant market penetration, reaching 82,000 patients across 50 countries, and capturing dynamic market share in psoriasis and rheumatology.
Negative Updates
Pricing Pressures in the U.S.
Continued price erosion is expected for CIMZIA due to IRA Part D redesign and rising trends of 340B, which could impact future revenue.
Currency Impact
The depreciation of the U.S. dollar is expected to be a stronger headwind in the second half of 2025, potentially impacting net sales.
Uncertainties with Tariffs
Potential tariffs on exports to the U.S. remain a concern, although the company has taken steps to mitigate immediate impacts.
Rising Operating Expenses
Marketing and selling expenses grew by 23% due to global launches and higher fees for service expenses in the U.S., which could affect future margins.
Company Guidance
During the UCB Half Year 2025 Capital Market Call, the company reported a remarkable 26% growth in net sales for the first half of the year, reaching EUR 3.32 billion. This growth was significantly driven by BIMZELX, which achieved nearly EUR 800 million in sales, quadrupling from the previous year. The company also highlighted a strong adjusted EBITDA of EUR 1.033 billion, reflecting a 58% increase and a margin expansion to 29.6%. UCB upgraded its full-year guidance, projecting at least EUR 7 billion in revenue and an EBITDA margin of at least 30%. The performance was bolstered by successful product launches and a robust pipeline, including BIMZELX's promising performance across multiple indications and strategic investments in manufacturing, such as a $2 billion U.S. greenfield investment. CFO Sandrine Dufour emphasized that despite pricing pressures, particularly in the U.S., the company remains committed to investing in its pipeline to sustain future growth.UCB SA Financial Statement Overview
Summary
UCB SA exhibits strong financial performance with significant revenue growth, high profitability margins, and solid cash flow generation. The balance sheet is stable with low leverage, providing a strong foundation for future growth.Income Statement
UCB SA's income statement reflects strong profitability with a robust gross profit margin of 71.6% and a net profit margin of 17.3% for 2024. The company has demonstrated significant revenue growth of 17.1% year-over-year, indicating a positive growth trajectory. Additionally, the EBIT margin is solid at 21.5%, and the EBITDA margin is impressive at 31.9%, showcasing operational efficiency.85
Very Positive
Balance Sheet
The balance sheet of UCB SA is solid, with a debt-to-equity ratio of 0.30, indicating low leverage and strong financial stability. The return on equity stands at 10.6%, reflecting moderate profitability relative to shareholder equity. The equity ratio is healthy at 57.8%, signifying a strong equity base relative to total assets.78
Positive
Cash Flow
UCB SA shows strong cash flow generation capabilities with a 106.7% growth in free cash flow. The operating cash flow to net income ratio is 1.17, indicating effective conversion of net income to cash. The free cash flow to net income ratio is 0.86, highlighting robust cash flow relative to profit, supporting the company's liquidity and investment capacity.82
Very Positive
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 6.15B | 5.25B | 5.52B | 5.78B | 5.35B |
| Gross Profit | 4.40B | 3.54B | 3.84B | 4.34B | 3.98B |
| EBITDA | 1.96B | 1.28B | 1.17B | 1.59B | 1.30B |
| Net Income | 1.06B | 343.00M | 418.00M | 1.06B | 732.00M |
Balance Sheet | |||||
| Total Assets | 17.35B | 15.54B | 15.87B | 14.21B | 13.32B |
| Cash, Cash Equivalents and Short-Term Investments | 1.76B | 923.00M | 1.14B | 1.48B | 1.52B |
| Total Debt | 3.03B | 3.04B | 2.90B | 2.12B | 2.75B |
| Total Liabilities | 7.32B | 6.56B | 6.80B | 5.82B | 6.05B |
| Stockholders Equity | 10.03B | 8.97B | 9.06B | 8.39B | 7.27B |
Cash Flow | |||||
| Free Cash Flow | 920.00M | 445.00M | 748.00M | 1.06B | 732.00M |
| Operating Cash Flow | 1.24B | 761.00M | 1.12B | 1.55B | 1.08B |
| Investing Cash Flow | 282.00M | -440.00M | -1.58B | -487.00M | -2.23B |
| Financing Cash Flow | -818.00M | -308.00M | 70.00M | -1.12B | 1.18B |
UCB SA Technical Analysis
Positive
120.83
Price Trends
110.50
Positive
101.13
Positive
97.53
Positive
Market Momentum
3.39
Positive
64.56
Neutral
56.15
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UCBJY, the sentiment is Positive. The current price of 120.83 is above the 20-day moving average (MA) of 118.50, above the 50-day MA of 110.50, and above the 200-day MA of 97.53, indicating a bullish trend. The MACD of 3.39 indicates Positive momentum. The RSI at 64.56 is Neutral, neither overbought nor oversold. The STOCH value of 56.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UCBJY.
UCB SA Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | 17.25B | 13.86 | 22.13% | ― | 23.25% | 64.46% | |
80 Outperform | 16.24B | 18.90 | 20.88% | ― | 18.87% | 1088.27% | |
78 Outperform | $45.75B | 31.74 | 13.80% | 0.73% | 26.28% | 457.14% | |
74 Outperform | 45.95B | 35.55 | 15.15% | ― | 89.58% | 0.00% | |
60 Neutral | 60.45B | -186.92 | -127.33% | ― | 5.01% | -330.09% | |
49 Neutral | 23.53B | -61.80 | -1.88% | ― | 7.51% | 30.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
UCBJY
UCB SA
120.83
32.98
37.54%
ALNY
Alnylam Pharma
461.24
186.78
68.05%
REGN
Regeneron
575.06
-566.79
-49.64%
ARGX
Argenx Se
752.32
230.10
44.06%
BNTX
BioNTech SE
99.26
-25.45
-20.41%
RPRX
Royalty Pharma
35.42
7.95
28.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.